Vitamin B~12~, also known as cobalamin (Cbl), is a micronutrient that is synthesised only by microorganisms, yet is essential to human health. Cobalamin was first isolated by Smith (Ref. [@ref1]) and Rickes (Ref. [@ref2]), after Minot and Murphy (Ref. [@ref3]) showed that pernicious anaemia could be treated with oral liver extract. Later, vitamin B~12~ deficiency as a result of genetic disease was described despite adequate vitamin intake (Ref. [@ref4]). Some patients responded successfully to very high doses of vitamin B~12~, suggesting blocks in vitamin processing. These patients had homocystinuria and/or methylmalonic aciduria, implicating dysfunctional methionine synthase (MS) and/or methylmalonyl-CoA mutase (MUT or MCM). We now know that blocks in the intracellular processing of cobalamin into cofactor forms, methylcobalamin (MeCbl) for MS and adenosylcobalamin (AdoCbl) for MCM, or in the functional activity of MS or MCM result in inborn errors. These genetic blocks may be devastating in newborns or in early childhood. Understanding the genes, gene products and subcellular transport of vitamin B~12~ is important for minimising the disease burden from these disorders. This review outlines the present knowledge of cobalamin metabolism, with a focus on steps related to the intracellular human pathway and the initial cataloguing of cobalamin-utilisation disorders into complementation groups and biochemically distinct classes. Key to these discoveries have been the hundreds of patients who have been the source of cell cultures and DNA samples that have given us our current understanding of vitamin B~12~ utilisation in humans.

Vitamin B~12~ structure {#sec2}
=======================

The structure of cobalamin was first solved by Hodgkin (Ref. [@ref5]) using x-ray crystallography. It is a large organometallic molecule, \~1300--1500 Da in size, and is the most chemically complex vitamin known. The focal point of vitamin B~12~ is the central cobalt atom, which has up to six ligands bound to it. Four of the ligands are the nitrogen atoms of the planar corrin ring that surround the cobalt atom ([Fig. 1](#fig01){ref-type="fig"}). The α-axial ligand, extending below the corrin ring, is a nitrogen of the 5,6-dimethylbenzimidazole (DMB) phosphoribosyl moiety that also attaches back to the corrin ring through one of its propionamide side chains. The upper or β-axial ligand varies, depending on the modification state of cobalamin (R-group in [Fig. 1a](#fig01){ref-type="fig"}). Functional β-axial ligands are methyl (MeCbl) or 5′-deoxyadenosyl (AdoCbl) groups. Additionally, a hydroxyl group (OHCbl) or a cyano group (CNCbl) can be bound as physiologically relevant β-axial ligands. Figure 1**Structure of vitamin B~12~ (cobalamin).** (a) The 'R group' corresponds to substitutions at the upper or β-axial ligand (5′-deoxyadenosyl-, methyl-, hydroxo-, cyano-). The dimethylbenzimidazole constituent (DMB) is shown coordinated to the cobalt in the lower α-axial position ('base-on' structure). DMB is linked to the corrin ring through a phosphoribosyl attached to a propionamide side chain. (b) Structure of methylcobalamin (MeCbl) with DMB displaced from the cobalt by a histidine residue in methionine synthase (MS; the 'base-off/His-on' structure). A similar configuration is observed for adenosylcobalamin (AdoCbl) bound to methylmalonyl-CoA mutase. Structures are from <http://www.genome.jp> using the 'SIMCOMP Search' utility (query C00576, vitamin B~12~; C06410, MeCbl-MS).

There are three important, inter-related factors that contribute to cobalamin reactivity and function: the oxidation state of cobalt; whether the DMB is coordinated to cobalt in the lower axial position; and the identity of the R-group bound in the upper axial position. The cobalt atom of cobalamin may exist in the +3 \[cob(III)alamin\], +2 \[cob(II)alamin\] or +1 \[cob(I)alamin\] oxidation state. AdoCbl, MeCbl, CNCbl and OHCbl, all of which are cob(III)alamins, prefer to adopt a configuration where the DMB nitrogen base is coordinated to the cobalt in the lower axial position (referred to as 'base-on') ([Fig. 1](#fig01){ref-type="fig"}). Some enzymes, however, are able to shift these cob(III)alamins to the 'base-off' configuration. Interestingly, MS and MCM, which use MeCbl and AdoCbl as cofactors, respectively, bind the cobalamin so that the DMB nitrogen is displaced from the cobalt and replaced by a histidine of the enzyme ([Fig. 1b](#fig01){ref-type="fig"}). This type of binding is considered 'base-off/His-on' and is important for the catalytic activity of the enzymes. Cob(II)alamin generally has no R-group bound, binding only DMB as the lower axial ligand to make its preferred five-coordinate state. However, in the presence of ATP, MMAB, the human adenosyltransferase (ATR) enzyme, is able to bind cob(II)alamin in a novel four-coordinate state, where neither axial position is occupied (Ref. [@ref51]). Cob(I)alamin usually has no axial ligand. It is a highly reactive nucleophile that very easily oxidises to cob(II)alamin (Ref. [@ref52]). The challenge to the cell is how to productively produce cob(I)alamin, as in the reaction cycle of MS, without exposing the local environment to nucleophillic attack and risk of free-radical damage. The nature of the axial ligands also affects the ease with which the central cobalt is reduced. Strongly coordinating ligands stabilise cobalt against reduction, whereas weakly coordinating ligands allow cobalt to be reduced more easily (Ref. [@ref53]). Base-on cobalamin falls into the former category, protecting the cobalt from reduction because DMB has greater electron-donating character than the H~2~O molecule that binds in its absence (Ref. [@ref54]).

Vitamin B~12~ origins {#sec3}
=====================

Vitamin B~12~ is an extremely old molecule in evolution. It has even been suggested that B~12~ was synthesised prebiotically (Ref. [@ref55]). Accordingly, vitamin B~12~ utilisation is dispersed throughout evolution, occurring in both Eukaryota and Prokaryota, perhaps having been passed on from the 'breakthrough organism' -- the last organism to use RNA as the sole genetically encoded catalyst (Ref. [@ref56]). Interestingly, although cobalamin utilisation is distributed widely among phyla, cobalamin synthesis seems limited to only a select few Archaea and Eubacteria. Perhaps this is because the synthesis of cobalamin is so complex -- involving in excess of 25 steps, which can proceed either aerobically (*cob* genes) or anaerobically (*cbi* genes) (Ref. [@ref57]). Therefore, although mammals and other higher organisms require vitamin B~12~ for life, they ostensibly acquire it from their prokaryotic counterparts. Another interesting facet of the evolution of cobalamin is that vitamin B~12~ users seem more scattered than logically spread out through evolution, with whole phyla sometimes gaining or losing vitamin B~12~ dependency (Ref. [@ref58]). Additionally, although mammals and other higher eukaryotes are restricted to two cobalamin-dependent enzymes, MS and MCM, prokaryotes use a plethora of enzymes requiring this cofactor. These enzymes include three classes of AdoCbl-dependent mutases, the isomerases (e.g. MCM, ribonucleotide reductase, glutamate mutase), the eliminases (e.g. diol dehydratase) and the aminomutases (e.g. [d]{.smallcaps}-lysine-5,6-aminomutase), as well as the MeCbl-dependent methyltransferases (e.g. MS) and the vitamin B~12~-dependent reductive dehalogenases (e.g. 3--6 chloro-4-hydroxybenzoate dehalogenase) (Refs [@ref59], [@ref60]). Therefore, because higher eukaryotes share common vitamin B~12~ ancestry with prokaryotes, but have apparently limited use of the vitamin and no biosynthesis, prokaryotes in general and a few specific bacteria and *Archaea* in particular have proved to be very useful models to understand vitamin B~12~ metabolism.

Human vitamin B~12~ ingestion and absorption {#sec4}
============================================

Because vitamin B~12~ is made by only a few microorganisms, it is acquired through dietary uptake in animals. Human dietary sources include milk, eggs, fish and meat in quantities in excess of a few micrograms a day (Ref. [@ref61]). In humans, the absorption, transport and cellular uptake of cobalamin is complex. Food-bound cobalamin is released in the stomach with the help of peptic activity, where it is subsequently bound by haptocorrin (HC) (Ref. [@ref62]). In the small intestine, cobalamin is released from HC by pancreatic protease digestion and bound by intrinsic factor (IF) to form an IF--Cbl complex. IF is very specific for cobalamin (i.e. for forms that have the lower DMB intact) and presumably acts as an early screening mechanism to prevent degraded cobalamins from intracellular access (Ref. [@ref63]). The IF--Cbl complex passes through the small intestine, where it is bound on the apical surface of ileal epithelial cells by a receptor composed of a heterodimer of amnionless and cubilin, called cubam, which aids in the endocytosis of IF--Cbl (Refs [@ref64], [@ref65]). Once inside the cell, IF is degraded in the lysosomes and cobalamin is released into the cytosol (Ref. [@ref66]), where it is transported across the ileal receptor cell and released into the bloodstream, possibly by the recently identified (with respect to vitamin B~12~ transport) multidrug resistance protein MRP1 (Ref. [@ref67]). In the bloodstream, cobalamin binds to either HC or transcobalamin (TC) (Ref. [@ref68]). Although HC binds the bulk of plasma cobalamin (75--90%), it is not involved in cellular cobalamin uptake apart from uptake in hepatocytes (Ref. [@ref68]). Therefore, individuals who have deficient or absent HC have serum cobalamin values in the deficient range, but show no sign of cobalamin deficiency (Ref. [@ref61]). Although TC binds only a minor fraction of circulating cobalamins (10--25%), it is the protein responsible for facilitating the uptake of cobalamin by cells (Refs [@ref69], [@ref70]). Mutations in the gene encoding TC (*TCN1*) result in severe tissue cobalamin insufficiency, megaloblastic anaemia, failure to thrive and often neurological complications, despite normal plasma cobalamin concentrations (Refs [@ref71], [@ref72]). Additionally, TC acts as a final screening mechanism because, like IF, TC is very specific for cobalamin forms that have the lower DMB intact (Refs [@ref73], [@ref74]). Treatment of TC deficiency requires very high serum cobalamin levels, ranging from 1000 to 10 000 pg/ml, achieved by oral or intramuscular delivery of 0.5--1.0 mg of CNCbl or HOCbl once or twice weekly (Refs [@ref60], [@ref75]). There is some evidence that at sufficiently high concentrations, at least some tissues are capable of taking up unbound cobalamin (Ref. [@ref61]). From the bloodstream, cobalamin is taken up into cells through receptor-mediated endocytosis as a complex of Cbl--TC bound to the TC receptor (TCblR) (Refs [@ref76], [@ref77], [@ref78]). A mutation in the gene encoding TCblR (*CD320*) was recently identified in asymptomatic newborns whose fibroblasts showed decreased Cbl uptake, where restoration of the missing codon by site-directed mutagenesis (c.262--264) resulted in normal TCblR function (Ref. [@ref79]). In the lysosome, the Cbl--TC complex is digested to create free cobalamin, which is subsequently transported into the cytosol probably as a mixture of cob(III)alamin and cob(II)alamin. Once in the cytosol, cobalamin is processed by many proteins, some known, others perhaps still unknown, to produce the cofactors MeCbl and AdoCbl. Failure to produce the cobalamin cofactors results in a lack of functional enzymes and causes the constellation of biochemical, developmental and neurological manifestations associated with intracellular pathway defects.

Complementation analysis for cataloguing the intracellular pathway of vitamin B~12~ disorders {#sec5}
=============================================================================================

The considerable range of clinical and biochemical heterogeneity observed in patients with vitamin B~12~ pathway disorders led to a need to sort them into genetically defined groups. The question of whether severe and mild disease or B~12~-responsive and -unresponsive forms could be explained by mutations in different genes was addressed early on by complementation analysis. This is a powerful technique that permits the identification of specific genes through their expression in fibroblast heterokaryons, multinucleate cells produced by the fusion of fibroblast strains from different patients, which could then be tested for restoration of function. To examine complementation, the incorporation of \[^14^C\]propionate or \[^14^C\]methyltetrahydrofolate \[or \[^14^C\]formate to methionine and serine (Ref. [@ref22])\] into trichloroacetic acid (TCA)-precipitable material was monitored by autoradiography of cells in situ or by direct scintillation counting of the TCA precipitate (Refs [@ref80], [@ref81]). Initially, four distinct complementation groups were identified, *cblA--cblC* and *mut.* However, over the years, the method came to be used diagnostically with hundreds of cell lines being analysed, mainly in the McGill University laboratory of David Rosenblatt, which became a dominant diagnostic centre using these techniques. So far, eight complementation groups, *cblA--cblG* and *mut*, have been described that have blocks in the production or utilisation of MeCbl, AdoCbl or both cofactors. Although all the genes corresponding to these disorders have now been described, many of their functions remain unclear. [Figure 2](#fig02){ref-type="fig"} illustrates the known or predicted functional location of the protein products of these genes. Three complementation groups -- *cblF*, *cblC* and *cblD* -- correspond to blocks in steps that are common to the synthesis of both cofactors with resulting deficiency of MS and MCM activities. Patients from these groups have combined homocystinuria and methylmalonic aciduria. Three groups, *cblD* variant 1, *cblE* and *cblG*, have blocks in the cytosolic pathway leading to MeCbl synthesis or apo-MS and result in deficient MS activity and homocystinuria. The final groups, *cblD* variant 2, *cblA*, *cblB* and *mut*, affect steps occurring in the mitochondrion leading to AdoCbl synthesis or apo-MCM and result in deficient MCM activity and methylmalonic aciduria. Figure 2**Intracellular processing of vitamin B~12~ showing sites of defects in complementation groups.** Complementation groups are in blue and are positioned at sites of metabolic blocks (shown in red). Cobalamin intermediates are in red. Excreted metabolites due to genetic defects are in shaded boxes. Pathway details are described in the text. In the lysosome, cobalamin is released from transcobalamin (TC) through its degradation (arrow pointing to dots). In the cytosol, R groups are released by the *cblC* protein with the cob(II)alamin \[Cob(II)\] product remaining bound (dotted line emanating from the *cblC* protein denotes complex with cobalamin forms). The three versions of the *cblD* protein (*cblD*, *cblD-1*, *cblD-2*) illustrate the role of the protein in directing cobalamin to the mitochondrial or cytosolic pathway. In the mitochondrion, the *cblB* protein adds the 5′-deoxyadenosyl group, generating the active cofactor \[adenosylcobalamin (AdoCbl)\], which is transferred to the *mut* \[methylmalonyl-CoA mutase (MCM)\] protein. The cblA protein is proposed to act as a gatekeeper to ensure that the cofactor form that is accepted and retained by MCM is AdoCbl. In the cytosolic pathway, cob(II)alamin is bound to the *cblG* \[methionine synthase (MS)\] protein. The *cblE* \[methionine synthase reductase (MSR)\] protein catalyses generation of the active cofactor, methylcobalamin (MeCbl), or its regeneration if oxidised to cob(II)alamin during reaction cycles.

Complementation groups affecting both methionine synthase and methylmalonyl-CoA mutase {#sec6}
======================================================================================

*cblF* {#sec6-1}
------

*cblF* was initially assigned to describe an infant with developmental delay and mild methylmalonic aciduria who was vitamin B~12~ responsive (Ref. [@ref82]). Her fibroblasts were found to accumulate free cobalamin, failing to attach to MS or MCM. By electron microscopy and subcellular fractionation, it was shown that most of the cobalamin was trapped in the lysosome, with only a small portion reaching the cytosol or mitochondria (Ref. [@ref83]). Complementation studies confirmed the genetically distinct disorder (Ref. [@ref84]). It was proposed that *cblF* represents a defect in the export of cobalamin out of the lysosome into the cytosol (Ref. [@ref82]). The gene responsible for *cblF* was very recently cloned by homozygosity mapping and microcell-mediated chromosome transfer and was found to correspond to *LMBRD1*, which encodes the lysosomal membrane protein LMBD1 (Ref. [@ref27]). LMBD1 shares homology with a family of membrane proteins that internalise lipocalins, which are carriers of small hydrophobic molecules such as steroids and lipids, leading to the suggestion that a lipocalin-like molecule may bind vitamin B~12~ in the lysosome on its release following TC degradation (Ref. [@ref27]). Transfection of *cblF* fibroblasts with intact cDNA corrected intracellular cobalamin processing and restored functional MS and MCM. The nature of the protein, with nine predicted transmembrane domains, and localisation of the protein to the lysosomal membrane, is consistent with a role in the export of cobalamin from the lysosome. Only 13 patients have been described with *cblF* (Refs [@ref27], [@ref28]). Six mutations have been identified, and, interestingly, all of them have been chain-terminating frameshift mutations, with one, 1056delG, accounting for 18 of 26 analysed alleles ([Fig. 3](#fig03){ref-type="fig"}). Clinically, it is a highly variable disorder. Most patients show failure to thrive in infancy and mild to severe developmental delay, but respond to vitamin B~12~ therapy. Although most patients presented with homocystinuria and methylmalonic aciduria, the index case, mentioned above, showed no evidence of megaloblastic anaemia or homocystinuria. This individual was reportedly asymptomatic on B~12~ therapy in adulthood, despite being homoallelic for the 1056delG mutation (Ref. [@ref27]). Figure 3**Mutations in the genes underlying the defects of the eight complementation groups.** For each complementation group, the gene name is given in brackets. Mutations are shown as cDNA position with corresponding amino-acid change in brackets. The numbering for each is based on the cDNA sequence: +1 corresponds to the A of the ATG translation initiation codon. Nonsense and frameshift (fs) mutations are displayed above the gene whereas missense and possible splice site or cryptic splice site (ss) mutations are displayed below. Mutations are based on *cblA* (Refs [@ref6], [@ref7], [@ref8], [@ref9], [@ref10]), *cblB* (Refs [@ref11], [@ref12], [@ref13]), *cblC* (Refs [@ref14], [@ref15], [@ref16], [@ref17], [@ref18], [@ref19]), *cblD* (Refs [@ref20], [@ref21]), *cblE* (Refs [@ref22], [@ref23], [@ref24], [@ref25], [@ref26]), *cblF* (Refs [@ref27], [@ref28]), *cblG* (Refs [@ref29], [@ref30], [@ref31], [@ref32]) and *mut* (Refs [@ref9], [@ref13], [@ref33], [@ref34], [@ref35], [@ref36], [@ref37], [@ref38], [@ref39], [@ref40], [@ref41], [@ref42], [@ref43], [@ref44], [@ref45], [@ref46], [@ref47], [@ref48], [@ref49], [@ref50]).

*cblC* {#sec6-2}
------

The *cblC* complementation group originally corresponded to the first set of patients who failed to produce either AdoCbl or MeCbl (Ref. [@ref85]). Since then, approximately 400 patients have been described with *cblC*, making it the most common disorder of intracellular vitamin B~12~ metabolism (Ref. [@ref14]). The gene responsible for the *cblC* group, called *MMACHC*, was identified by homozygosity mapping in 2006 (Ref. [@ref15]). More than 50 different disease-causing mutations have been identified and are summarised in Ref. [@ref14] ([Fig. 3](#fig03){ref-type="fig"}). The most common is the c.271dupA mutation, which causes a frameshift truncation, accounting for 42% of pathogenic alleles (Ref. [@ref14]). Additionally, the c.394C \> T (R132X) and c.331C \> T (R111X) mutations are found commonly, at 20% and 5% of alleles, respectively. Although all *cblC* patients have combined homocystinuria and methylmalonic aciduria and often have haemotological, neurological and ophthalmic abnormalities to some degree, they tend to fall into either of two distinct phenotypes correlating with age of onset (Ref. [@ref86]). Early-onset patients present in the first year of life with severe disease and rarely respond clinically to treatment, whereas late-onset patients present in childhood to adulthood, are more likely to have less severe symptoms, and usually respond better to treatment (Ref. [@ref86]). A strong genotype*--*phenotype correlation can be found with some mutations: the c.271dupA and c.331C \> T (R111X) mutations usually cause the much more prevalent early-onset disease, whereas some missense mutations \[e.g. c.482G \> A (R161Q)\] and, bewilderingly, the c.394C \> T (R132X) nonsense mutation usually result in late-onset disease (Refs [@ref14], [@ref15]). The *cblC* protein (MMACHC) was predicted to have a vitamin B~12~ binding site and a TonB-like domain; the latter is a protein associated with bacterial cobalamin uptake (Ref. [@ref15]). Although initial studies suggested that MMACHC had base-on CNCbl binding (Ref. [@ref87]), it was later demonstrated to bind CNCbl in the base-off conformation (Ref. [@ref88]) and to reductively cleave the CN group to form MMACHC-bound cob(II)alamin (Ref. [@ref87]). It has also been shown to catalyse glutathione-dependent dealkylation of cobalamins containing C2--C6 alkanes, Ado-, or Me- as the upper axial ligand (Ref. [@ref89]). These results suggest that MMACHC might be involved in intracellular cobalamin transport and reductive dealkylation or decyanation, perhaps interacting with the *cblF* protein for export of cobalamin out of the lysosome and beginning the initial processing of cobalamin, yielding cob(II)alamin, before passing it along for distribution to the rest of the pathway (Refs [@ref14], [@ref62]) ([Fig. 2](#fig02){ref-type="fig"}).

Late-onset *cblC* patients are cobalamin responsive but, as observed initially in fibroblasts and later in patients, they respond poorly to CNCbl compared with OHCbl, a phenomenon that is unique among the vitamin B~12~ disorders (Refs [@ref86], [@ref90], [@ref91], [@ref92]). Investigations of cobalamin binding by wild-type and mutant protein, the latter containing the R161Q mutation commonly associated with OHCbl responsiveness in *cblC* patients, revealed reduced binding of CNCbl but not OHCbl by the mutant protein compared with the wild type (Ref. [@ref93]). Further, thermolability studies showed that MMACHC protein is strongly stabilised by cobalamin binding, whereas mutant protein was much less stabilised and only minimally or not at all with CNCbl (Ref. [@ref87]). These results suggest that OHCbl responsiveness in patients with the R161Q mutation is due to a combination of better affinity for OHCbl than CNCbl and a much better stabilisation of the mutant protein by OHCbl. It may well be that the high-dose OHCbl treatment generally used with *cblC* patients protects the protein from degradation in vivo. An interesting outcome of these studies was the finding that the cobalamin cofactors, AdoCbl and MeCbl, were far more protective of the mutant protein than OHCbl. Although treatment with AdoCbl or MeCbl has been tried before, it was found that they are not incorporated directly as cofactors of their cognate enzymes but are dealkylated and processed anew, results that have been confirmed in vitro with MMACHC (Refs [@ref89], [@ref94]). However, the increased stabilisation of mutant protein afforded by the cofactors suggests that their use should be re-examined in some cases.

*cblD* {#sec6-3}
------

The *cblD* complementation group was first described in two siblings with combined homocystinuria and methylmalonic aciduria and deficiency of MCM and MS activities (Ref. [@ref95]), although the designation '*cblD*' was not given until many years later (Ref. [@ref81]). For over 25 years, they remained the only *cblD* patients described, and biochemical analysis revealed that only this complementation group seemed to behave in a manner similar to *cblC*, but with less severe defects (Ref. [@ref91]). However, in 2004, Suormala et al. (Ref. [@ref96]) described three new cases of *cblD:* two had only MS deficiency (called *cblD* variant 1) and one had only MCM deficiency (*cblD* variant 2). These results suggested that the *cblD* protein might be responsible for branching of the cobalamin metabolism pathways to the cytosolic or mitochondrial compartments ([Fig. 2](#fig02){ref-type="fig"}). The same group cloned the *cblD* gene 4 years later (Ref. [@ref20]), naming it *MMADHC*. With an additional four patients they showed a clear genotype--phenotype relationship, whereby truncation mutations in the 5′ region resulted in only methylmalonic aciduria (MCM deficiency), truncation mutations in the middle and 3′ regions resulted in combined methylmalonic aciduria and homocystinuria (MCM and MS deficiency), and missense mutations in the 3′ region resulted in only homocystinuria (MS deficiency) ([Fig. 3](#fig03){ref-type="fig"}). Transfection experiments demonstrated correction of the defect in mutant fibroblasts. In particular, a cDNA constructed with a 5′-truncation mutation could correct the synthesis of MeCbl, suggesting that an internal translation initiation site is probably functional. Additionally, they demonstrated that the *cblH* complementation group, which had been previously described for one patient with unidentified methylmalonic aciduria (Ref. [@ref97]), was actually an example of *cblD* variant 2 ([Fig. 2](#fig02){ref-type="fig"}). MMADHC has a predicted mitochondrial leader sequence and a putative vitamin B~12~ binding sequence and shows limited homology to a bacterial ABC transporter (Ref. [@ref20]). Although no functional or biochemical data are yet available for MMADHC, it is currently speculated to interact with MMACHC as part of a chaperone role to present cobalamin to the cytosolic or mitochondrial pathways (Refs [@ref20], [@ref62]).

Complementation groups affecting only methionine synthase {#sec7}
=========================================================

In 1984, Schuh and colleagues (Ref. [@ref98]) described an infant with homocystinuria, megaloblastic anaemia and developmental delay who, although treatable with cobalamin, showed no evidence of methylmalonic aciduria, a novel outcome at the time. This suggested that the infant had a unique block in MS or the synthesis of MeCbl. Subsequently, two other patients were described with the same symptoms (Refs [@ref99], [@ref100]). Broken cell extracts from the original patient revealed that with added reducing agents, MS worked perfectly. However, this was not the case for MS from the next two patients. Their cell extracts were defective regardless of additions. Ultimately, Watkins and Rosenblatt (Ref. [@ref101]) used complementation analysis to show that the original patient, designated as *cblE*, had a block in a separate genetic locus to the other two patients, which they designated as *cblG* ([Fig. 2](#fig02){ref-type="fig"}).

*cblG* {#sec7-1}
------

The gene responsible for *cblG* was cloned by three separate groups based on the identification of human sequences homologous to the *E. coli* vitamin-B~12~-dependent MS, encoded by the *metH* gene, and other bacterial and *Caenorhabditis elegans* sequences (Refs [@ref29], [@ref102], [@ref103]). The human gene is designated *MTR*, for methyltransferase, as it was named when initially mapped to human chromosome 1 (Ref. [@ref91]), or more formally as 5-methyltetrahydrofolate:homocysteine methyltransferase. Twenty different mutations have been identified in *MTR* ([Fig. 3](#fig03){ref-type="fig"}). The most common is c.3518C \> T (P1173L), which is present in 16 of 24 *cblG* cell lines surveyed (Ref. [@ref30]). The clinical disease is highly variable, with onset ranging from neonatal to adulthood, although most patients present with homocystinuria, hypomethioninaemia, megaloblastic anaemia and developmental delay (Refs [@ref101], [@ref104], [@ref105], [@ref106]). In addition to its importance in protein synthesis, MS is a key enzyme of the methionine cycle, which maintains the cellular level of the methionine derivative, *S*-adenosylmethionine, the methyl donor in a wide array of cellular processes including DNA, RNA and protein methylation. It is also uniquely involved in the folate cycle, because it is the only mammalian enzyme to use 5-methyltetrahydrofolate as a methyl donor (Ref. [@ref30]). MS catalyses the methylation of homocysteine to form methionine in a reaction that requires the presence of enzyme-bound MeCbl for activity (Refs [@ref107], [@ref108]). The reaction proceeds by methyl transfer from 5-methyltetrahydrofolate to MS-bound cob(I)alamin to form MeCbl, followed by transfer of the methyl group to homocysteine to form methionine and regeneration of cob(I)alamin (Refs [@ref109], [@ref110]). Mammalian MS and *Escherichia coli* MetH are 55% identical (Ref. [@ref103]). The sequence homology extends to the domain structure of MetH in which linearly arrayed domains of the enzyme contain binding sites for the various substrates and cofactors (Refs [@ref111], [@ref112], [@ref113]). These domains seem to be faithfully maintained in mammalian MS.

*cblE* {#sec7-2}
------

Because the reaction catalysed by MS regenerates cob(I)alamin in every reaction cycle, the cofactor risks occasional oxidation to cob(II)alamin with consequent inactivation of the enzyme (Ref. [@ref114]). In *E. coli*, the restoration of a functional cofactor is dependent on two flavoproteins, flavodoxin and flavodoxin reductase, containing flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) prosthetic groups, respectively (Refs [@ref115], [@ref116]). The corresponding human reducing system proved to be encoded by a single gene, *MTRR*, which is mutated in *cblE* patients ([Fig. 3](#fig03){ref-type="fig"}); it encodes a single protein containing FMN- and FAD/NADPH-binding sites (Ref. [@ref117]). This enzyme, named methionine synthase reductase (MSR), is a linear array of 'flavodoxin' at the N-terminus, an intervening linker sequence in the middle and 'flavodoxin reductase' at the C-terminus. It restores MS activity by catalysing the reductive methylation of cob(II)alamin on the inactivated MS in which *S*-adenosylmethionine is the source of the methyl group (Refs [@ref118], [@ref119]). Additionally, MSR has been shown to catalyse the reduction of free B~12~ \[as aquocob(III)alamin\] to cob(II)alamin (Ref. [@ref120]), making it an aquocobalamin reductase and possibly functioning as such in the cytosolic pathway. MSR has also been suggested to function as a cob(II)alamin reductase in the mitochondrial pathway. This hypothesis was based on a potential mitochondrial leader sequence found by alternative splicing in the *MTRR* gene, as well as in vitro results demonstrating the production of cob(I)alamin through physical interaction with the mitochondrial MMAB protein (Refs [@ref117], [@ref121]). However, evidence demonstrating MSR expression only in the cytosol (Ref. [@ref122]) and separate evidence suggesting that MMAB does not require a distinct cobalamin reductase (Ref. [@ref123]) have strongly countered this argument. The clinical presentation of *cblE* patients is similar to that of *cblG* patients. It is usually impossible to separate the two disorders, except for one patient who unexpectedly also had methylmalonic aciduria (Ref. [@ref105]), which remains unexplained.

Complementation groups affecting only methylmalonyl-CoA mutase {#sec8}
==============================================================

Patients with methylmalonic aciduria without elevated homocysteine or abnormalities of circulating vitamin B~12~ have defects in the mitochondrial pathway of AdoCbl synthesis and functional MCM. Clinically, patients have the following common features: failure to thrive, lethargy, vomiting of protein feeds, dehydration, respiratory distress and hypotonia (Ref. [@ref124]). Early on, three genes were implicated in the mitochondrial pathway, corresponding to complementation groups *cblA*, *cblB* and *mut* (Refs [@ref80], [@ref85]) ([Fig. 2](#fig02){ref-type="fig"}). A detailed understanding of the mitochondrial processing of vitamin B~12~ is only now beginning to emerge, based largely on studies completed on bacterial model systems.

*cblA* {#sec8-1}
------

*cblA* was initially the designation for patient fibroblasts that failed to accumulate AdoCbl in intact cells, but showed restored AdoCbl synthesis in a broken-cell assay with OHCbl, ATP and a reducing system (Ref. [@ref85]). This block was hypothesised to correspond to a defect in mitochondrial cob(II)alamin reductase because of the ability of an external reducing system to alleviate the block (Ref. [@ref85]). The human gene, named *MMAA*, was identified in a search for genes clustered in proximity to MCM (*mut*) in microbial genomes and while searching for orthologous sequences in the human genome (Ref. [@ref6]). Examination of the sequence of *MMAA*, however, revealed that it did not encode a reductase, but rather a protein that belonged to the G3E family of P-loop GTPases, a group of proteins that participate in the assembly or function of the metal centres in metalloenzymes (Ref. [@ref6]). More than 30 *cblA* patient mutations have been described in the *MMAA* gene, with most of them corresponding to nonsense or frameshift mutations ([Fig. 3](#fig03){ref-type="fig"}). Although most *cblA* patients present in infancy or childhood with methylmalonic aciduria and potentially life-threatening acidotic crises (Ref. [@ref104]), they often respond to vitamin B~12~ therapy despite the severity of mutations (Refs [@ref104], [@ref124], [@ref125]). Reasons for this are becoming clearer because of our increased understanding of the role of MMAA. Studies have focused on the bacterial orthologues of MMAA, including key research by Banerjee and colleagues working with MeaB, the MMAA orthologue from *Methylobacterium extorquens*. Initial bacterial studies showed that MMAA orthologues form a complex with MCM and that GTP binding and hydrolysis contribute to cobalamin processing (Refs [@ref126], [@ref127], [@ref128]). Further, it was shown that MeaB protects MCM from inactivation and that the state of MeaB (apo, GDP or GTP bound) alters the affinity of MCM for AdoCbl (Ref. [@ref129]). Finally, recent studies suggest that MeaB acts as a regulator of MCM cofactor binding and ejection, where the binding and hydrolysis of GTP by MeaB are important in the discrimination of MCM binding to AdoCbl versus cob(II)alamin, and promotes ejection of the latter, inactive cofactor from MCM (Ref. [@ref130]). These studies are summarised below in the proposed model for cobalamin processing.

*cblB* {#sec8-2}
------

Patients in the *cblB* group are also deficient in AdoCbl synthesis and are metabolically similar to *cblA* (Ref. [@ref86]). However, *cblB* patients tend to present earlier, respond more poorly to vitamin B~12~ and, consequently, may produce a more severe clinical course with more profound neurological and metabolic complications (Refs [@ref124], [@ref125]). The *cblB* disorder was separated biochemically from *cblA* by the failure to synthesise AdoCbl in broken cell extracts containing a reducing system (Ref. [@ref85]). On the basis of this early work, *cblB* had long been expected to correspond to a defect in the ATP:cob(I)alamin ATR. Like *MMAA*, the gene was identified in the survey of MCM-containing gene clusters in microbial genomes (see the previous section) and was named *MMAB* (Ref. [@ref11]). It was shown to correspond to an ATR based on sequence and functional similarity with a class of bacterial ATRs called PduO (Refs [@ref11], [@ref131]). The MMAB protein catalyses the transfer of the 5′-deoxyadenosyl group of ATP to cob(I)alamin to form AdoCbl. To assess function, cob(II)alamin is the usual cobalamin added in vitro, with a reducing system, often MSR and NADPH, added to facilitate the reaction. Unexpectedly, in the presence of ATP, MMAB binds cob(II)alamin in an unusual base-off, four-coordinate state (Ref. [@ref51]). This unusual binding elevates the redox potential of cob(II)alamin to the physiological range of possible reduction by reduced flavin, perhaps in the form of an electron transfer protein, thus obviating the need for a specific cobalamin reductase to generate the reactive cob(I)alamin intermediate (Ref. [@ref123]). Most of the mutations identified in *cblB* disease were found to cluster in exon 7, which encodes the active site of the enzyme (Refs [@ref12], [@ref132]) ([Fig. 3](#fig03){ref-type="fig"}). Several mutations have been modelled in human and microbial ATRs, identifying defects in substrate or cofactor binding, active site functions or protein dynamics (Refs [@ref132], [@ref133], [@ref134], [@ref135], [@ref136]). Interestingly, two of the mutations (R186W, E193K) resulted in absent protein in western blots of patient cell extracts, suggesting protein instability as a major contributor to disease phenotype (Ref. [@ref137]). Human MMAB has been crystallised in the presence of ATP (Ref. [@ref132]). It was found to exist as a trimer with three active sites, only two of which contained ATP. Crystallisation in the presence of both ATP and cob(II)alamin has been accomplished for the *Lactobacillus reuteri* ATR (*Lr*PduO) (Ref. [@ref135]). The two enzymes are highly similar and, interestingly, AdoCbl was detected in *Lr*PduO crystals, underscoring the capacity of reduced flavin, generated in the incubation mix, to drive the four-coordinate cob(II)alamin intermediate to cob(I)alamin and the formation of AdoCbl.

*mut* {#sec8-3}
-----

The *mut* complementation group is representative of mutations in the *MUT* (MCM) gene. MCM is important for the metabolism of branched-chain amino acids, odd-chain fatty acids and cholesterol (Ref. [@ref104]). It catalyses the reversible isomerisation of [l]{.smallcaps}-methylmalonyl-CoA to [l]{.smallcaps}-succinyl-CoA ([Fig. 2](#fig02){ref-type="fig"}), which is important for the breakdown of propionate and for replenishing the tricarboxylic acid cycle. The *MUT* gene was the earliest of the human B~12~ pathway genes to be cloned, accomplished by antibody screening of a human liver λgt11 expression library (Ref. [@ref138]). Nearly 200 disease-causing mutations have been identified in *MUT* (Ref. [@ref33]) ([Fig. 3](#fig03){ref-type="fig"}). Two distinct classes of mutations have been described: *mut*^−^ ('mut-minus'), when there is residual enzyme activity or detectable \[^14^C\] propionate incorporation by mutant fibroblasts; and *mut*^0^ ('mut-zero'), when protein or enzyme activity is not detected, as found, for example, in frameshift or chain-terminating mutations and some amino-acid substitutions (Refs [@ref139], [@ref140]). Unsurprisingly, these two groups separate patients clinically. *mut*^0^ patients have a higher occurrence of morbidity, mortality and neurological complications than *mut*^−^, and *mut*^−^ patients are more responsive to B~12~ therapy (Ref. [@ref124]). MCM from *Proprionibacterium shermanii* has been crystallised in the presence of AdoCbl and substrate (PDB accession number 4REQ) (Refs [@ref141], [@ref142], [@ref143]). The human enzyme (PDB accession number 3BIC) is structurally similar to the *P. shermanii* enzyme, with which it shares 60% identity in the α-subunit (Ref. [@ref144]). Human MCM exists as a homodimer in the mitochondrial matrix with 1 mol of AdoCbl bound per subunit (Refs [@ref145], [@ref146]). Studies of the *Methylobacterium extorquens* enzyme, as described above, suggest that human MCM does not exist alone but functions as a complex with other proteins, notably MMAA and possibly MMAB.

Model for the intracellular processing of vitamin B~12~ {#sec9}
=======================================================

The genes and proteins corresponding to all eight complementation groups defined in patients have provided most of the elements required to describe the intracellular processing of vitamin B~12~ ([Fig. 2](#fig02){ref-type="fig"}). Cobalamin, generally as OHCbl or CNCbl, is taken into the lysosome as a Cbl--TC complex, where digestion of the transcobalamin releases free cobalamin. The cobalamin is transported into the cytosol through the LMBD1 protein, possibly drawn through the lysosomal transporter by interaction of the cytosol face of LMBD1 with the MMACHC protein. It appears that cobalamins are bound to MMACHC in the base-off state, poised for cleavage of the upper axial ligand if one is present. MMACHC may act as an intracellular cobalamin carrier for delivery of the cofactor to the MMADHC protein for targeting to the cytosolic (MS) or mitochondrial (MCM) pathways. Evidence of interaction of MMACHC with either LMBD1 or MMADHC has yet to be demonstrated. In the cytosolic compartment, cob(II)alamin is expected to be bound to MS, where it is reductively methylated by MSR, using NADPH as an electron donor, to generate the MeCbl active cofactor of MS. MMADHC also participates in the targeting of cobalamin to the mitochondrial pathway, although the specific transporter has yet to be identified. Cob(II)alamin, on entry into the mitochondrial matrix, is bound by MMAB for the generation of AdoCbl, with the reducing equivalents probably coming from an electron transfer protein rather than a cobalamin reductase, as had been previously anticipated. The subsequent transfer of AdoCbl to MCM is predicted to be an exquisitely complicated process involving a complex of MMAA and MCM and possibly MMAB.

First, the complex of MCM:MMAA--GTP prevents the binding of cob(II)alamin, which would otherwise inactivate MCM. Second, AdoCbl is transferred directly from MMAB to the MCM--MeaB--GTP complex in a process requiring ATP binding to MMAB and GTP hydrolysis by MMAA. Third, in reaction cycles in which the radical 5′deoxyadenosyl intermediate is lost, leaving MCM with an inactive cob(II)alamin cofactor, the GTP-bound MMAA causes displacement of the cofactor, making the enzyme available for renewed AdoCbl binding. The proposed role for MMAA derives principally from studies of MeaB by Padovani and Banerjee (Refs [@ref127], [@ref129], [@ref130]). The crystal structure of MeaB has been determined and carries the expected nucleotide-binding domains and domains predicted to be involved in MCM binding at the N-terminus and a dimerisation domain at the C-terminus (PDB accession number 4REQ) (Ref. [@ref147]). The recently crystallised human MMAA (PDB accession number 2WWW), although it has a similar overall structure, seems to adopt a slightly different mode of assembly, which may have implications for the three-way interaction with MMAB and MCM.

Research in progress and outstanding research questions {#sec10}
=======================================================

Although all eight genes predicted through complementation analysis have been identified, additional genes are anticipated. Most notably, the mechanism of the mitochondrial transport of B~12~ remains unknown. The involvement of *cblD* defects in both the cytosolic and mitochondrial pathways suggests that the MMADHC protein is an accessory to the mitochondrial uptake of vitamin B~12~. The lysosomal delivery of vitamin B~12~ to the cytosol might also involve additional genes. The similarity of LMBD1 to the lipocalin family of membrane receptors predicts the involvement of a lipocalin-like molecule that might act as a vitamin B~12~ carrier after digestion of the Cbl--TC complex in the lysosome. Although a mitochondrial cobalamin reductase cannot be fully ruled out, studies on PduO-type ATRs argue against such a protein in human cells. Finally, if confirmed in human cells, the MMAA--MCM or MMAA--MCM--MMAB complex predicted by studies on MeaB proteins might account for the gene set required for mitochondrial cobalamin processing and utilisation. All these suggestions recognise the absence of additional disease states among human vitamin B~12~ processing disorders. The general view is that unidentified genes would probably not tolerate mutation (and therefore be lethal embryonically), might be associated with shared functions (and therefore might not reveal a vitamin B~12~ disease phenotype) or might be redundant with genes encoding proteins of similar function (allowing a bypass of a genetic defect). Therefore, completion of the human pathway requires either finding new genes or demonstrating that the pathway is fully functional without them. One approach might be to investigate the pathway in a model eukaryotic organism carrying orthologues of most (or all) the human genes, as suggested in studies of the methylmalonate pathway in *C. elegans*, an organism with knockout mutants of several vitamin B~12~ pathway genes (Refs [@ref148], [@ref149], [@ref150]).

Although we have gained much insight into the pathway of vitamin B~12~ metabolism, the goal of the medical geneticist has been to gain insight into managing the vitamin B~12~ disorders, providing access to carrier testing and prenatal diagnosis, and, in the best of outcomes, preventing or successfully treating symptomatic disease. The remarkable feature of vitamin B~12~ utilisation disorders has been their potential for treatment. The discovery that high-dose vitamin B~12~ can overcome pathway deficits in some patients has given new life to individuals with an otherwise potentially severe or fatal disease. The early discovery that OHCbl is effective in the treatment of *cblC* disorder while CNCbl is not is a powerful illustration of the complexity of vitamin B~12~ biochemistry. The more recent finding that AdoCbl or MeCbl may have a significant stabilising effect on MMACHC protein, despite ultimately being hydrolysed to cob(II)alamin, reminds us that there is still much to be learned on behalf of the patient. Strikingly, the most recent success with gene therapy to treat mice with knockout of the *Mut* gene (Ref. [@ref151]) has opened up a new avenue for treatment that might ultimately benefit patients with metabolically 'unresponsive' disorders. The application of widespread newborn screening for homocysteine and methylmalonate underscores the opportunity to identify and treat these patients before the onset of potentially irreversible disease.
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